1Schiller JH,Kim KM,Hufson P,et al. Phase 1 study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol, 1996t 14:2345-2352.
2Watanabe K,Fukuoka M, Niitani H. Phase 1 trial of topotecan for small cell lung cancer (SCLC). Lung Cancer, 1997 ; 18 (suppll) : 58.
3Depierre A, yon Pawel J, Hans K, et al. Evaluation of topoteean (Hycarotin) in relapsed small cell lung cancer (SCLC): a multicentre phase I study abstract. Lung Cancer, 1997 ; 18(suppll) : 35.
4Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer:a phase I study in patients with refractory and sensitive disease. J Clin Oncol, 1997,15 : 2090- 2096.
5Brahmer JR,Ettinger DS. The Role of Topoteean in the Treatment of Small Cell Lung Caner. Oncologist, 18998,3 ( 1 ) : 11 - 14.
6Schiller, JH, yon Pawel, J, Clarke, P, et al. Preliminary results of a randomized comparative phase Ⅲ trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC). LungCancer, 1997 , 18 (suppll) :13-14.
7Negoro,S,Fukuoka,M,Nitani,H,et al.A phase 1 study of CPT-11 ,a camptothecin derivative in patients with primary lung cancer.Jpn J Cancer Chemot her, 1991,18 : 1013 - 1019.
8Saudler AB,Irinotecan in small cell lung cancer :the US experience.Oncology, 2001,15(11):11 - 12.
9Nishiwaki Y,Kawahara M,et al. Irinotecan plus cisplatin complatin compared with etoposide pule cisplatin for estehsive small-cell lung cancer. N Engl J Med,2002,346(2):126-128.
10Kakolyris S,Mavroudis D,Tsavaris N,et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase Ⅱ study. Ann Oncol,2001,12(2):193-197.
